Novavax, Inc

Novavax is a U.S.-based biotechnology company focused on developing and commercializing protein-based vaccines and vaccine-related technologies. Its core business centers on its COVID-19 vaccine franchise, recombinant nanoparticle vaccine platform, and Matrix-M adjuvant, supported through collaborations with pharmaceutical partners and government procurement arrangements.

42,8 %

93,5 %

39,2 %

+64,7 %

2.13

2.10

— Novavax, Inc
%
COVID-19 vaccines70% Commercial and government-supplied COVID-19 vaccine products and related formulations.
Licensing, royalties and milestones20% Revenue from collaboration agreements, milestone achievements, and royalty streams.
Adjuvant and material supply7% Sales of Matrix-M adjuvant and other materials supplied to partners.
Transition services and technology transfer3% Services provided to partners during product transfer and commercialization transitions.

Novavax sells primarily to pharmaceutical partners, governments, and wholesale distributors rather than directly to a...

  • Government procurement agenciesprimary

    Buy vaccine doses under APAs and settlement arrangements to support public immunization programs.

  • Pharmaceutical collaboratorsprimary

    License Novavax technology, fund development, and commercialize products in specific markets.

  • Wholesale distributorssecondary

    Distribute commercial vaccine supply in markets where Novavax or a partner is the commercial lead.

  • Other vaccine partnerssecondary

    Purchase adjuvant, materials, and related supply items for use in partner vaccine programs.

Novavax is headquartered in the United States but operates through a global collaboration and supply network...

  • •Headquartered in the United States
  • •Commercial and collaboration activity spans multiple global markets
  • •Revenue depends on foreign government and partner agreements
  • •Swedish subsidiary Novavax AB supports international operations
  • •Cross-border business creates regulatory, currency, and trade exposure

Novavax’s strategy is centered on its COVID-19 vaccine franchise, partner-led commercialization, and monetization of...

01
Commercialize COVID-19 vaccines through partnersshort-term

Partner-led distribution reduces the need for a large direct sales force and broadens market access.

02
Monetize the Matrix-M platformmedium-term

Licensing and supply agreements create non-dilutive revenue from the adjuvant technology base.

03
Expand beyond COVID-19medium-term

Broader pipeline development can diversify revenue and reduce dependence on one vaccine franchise.

Novavax faces substantial execution and funding risk because its business depends on successful vaccine development,...

critical

Funding and going-concern risk

The company requires significant funding to maintain operations and advance its pipeline.

Scope
Cash runway, capital raising, debt refinancing
Materiality
high
high

Dependence on collaboration and supply agreements

Revenue and commercialization depend on third parties that control distribution, milestones, and market execution.

Scope
Sanofi CLA, APAs, Takeda, SII, SK bioscience
Materiality
high
high

Regulatory and clinical development risk

Vaccine candidates must succeed in trials and obtain approvals before generating durable commercial value.

Scope
COVID-19, influenza, combination vaccine programs
Materiality
high
medium

International operating and compliance risk

The company operates through cross-border agreements and faces local regulatory, tax, and anti-bribery requirements.

Scope
Europe, Asia, foreign governments
Materiality
medium
medium

Competitive pressure

Larger vaccine companies can move faster on development, manufacturing, and commercialization.

Scope
COVID-19 and combination vaccine markets
Materiality
medium
Revenue recognition for collaboration agreements
Can create large swings in reported revenue between periods
Product returns and gross-to-net deductions
Affects the timing and amount of recognized product sales
Deferred revenue and milestone accounting
Can shift revenue recognition across quarters and years
Settlement and termination accounting
May distort comparability with underlying commercial demand

NOVAVAX INC

NVAX · Biological Products, (No Diagnostic Substances)

NORTHWEST BIOTHERAPEUTICS INC

NWBO · Pharmaceutical Preparations

Nuvation Bio Inc.

NUVB · Pharmaceutical Preparations

Nuvalent, Inc.

NUVL · Pharmaceutical Preparations

DYNAVAX TECHNOLOGIES CORP

Pharmaceutical Preparations

Innoviva, Inc.

INVA · Pharmaceutical Preparations

: 29/04/2026